Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
5.61
+0.61 (12.20%)
At close: Dec 20, 2024, 4:00 PM
5.54
-0.07 (-1.25%)
After-hours: Dec 20, 2024, 7:50 PM EST
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Sage Therapeutics stock have an average target of 11.53, with a low estimate of 4.00 and a high estimate of 26. The average target predicts an increase of 105.53% from the current stock price of 5.61.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for SAGE stock from 19 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 16 | 16 | 16 | 15 | 16 | 15 |
| Sell | 1 | 1 | 1 | 2 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 19 | 20 | 20 | 20 | 20 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold Maintains $10 → $6 | Hold | Maintains | $10 → $6 | +6.95% | Dec 16, 2024 |
| TD Cowen | TD Cowen | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | +60.43% | Nov 21, 2024 |
| RBC Capital | RBC Capital | Sell → Hold Upgrades $4 | Sell → Hold | Upgrades | $4 | -28.70% | Nov 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $14 | Hold | Reiterates | $14 | +149.55% | Nov 20, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 20, 2024 |
Financial Forecast
Revenue This Year
43.17M
from 86.46M
Decreased by -50.07%
Revenue Next Year
96.12M
from 43.17M
Increased by 122.66%
EPS This Year
-6.70
from -9.05
EPS Next Year
-3.98
from -6.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 47.9M | 182.8M | 550.2M | |||
| Avg | 43.2M | 96.1M | 161.2M | |||
| Low | 38.0M | 37.9M | 71.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -44.6% | 323.5% | 472.4% | |||
| Avg | -50.1% | 122.7% | 67.7% | |||
| Low | -56.0% | -12.3% | -26.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -6.27 | -0.85 | -1.06 | |||
| Avg | -6.70 | -3.98 | -2.89 | |||
| Low | -7.33 | -5.18 | -4.72 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.